| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2195 | Fxia-in-1 | Novel potent and selective inhibitor of FXIa, producing a robust and dose-dependent inhibition of both arterial thrombosis and MES |
|
| DCC2196 | fxr-in-12u | Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonist |
|
| DCC2197 | G202-0362 | Novel antiviral agent against Rift Valley fever virus (RVFV) by blocking virus budding from the trans Golgi. |
|
| DCC2198 | G-38963 | Novel potent and highly specific MEK inhibitor (MEKi) |
|
| DCC2199 | G4-dna Ligand-3 | Novel fluorescent specific ligand of human telomeric G-quadruplex DNA, binding to both G-tetrad and the lateral loop near the 5-end, reducing the telomere length and downregulating hTERC and hTERT mRNA expression in HeLa cells |
|
| DCC2200 | G514-0206 | Inhibitor of NLRP3 inflammasome |
|
| DCC2201 | G6 Hydrochloride | Novel antibacterial and anti-biofilm agent against antibiotic resistant clinical isolates |
|
| DCC2202 | G6pdi-1 | Novel G6PD inhibitor, revealing immune dependence on pentose phosphate pathway. depleting NADPH most strongly in lymphocytes, markedly decreasing inflammatory cytokine production in T calls, suppressing respiratory burst in neutrophils |
|
| DCC2203 | Gabaar Antagonist 1e | Novel potent competitive γ-aminobutyric acid type A receptor (GABA A R) antagonist (K i = 180 nM), targeting extrasynaptic α4βδ subtype, showing efficiently rescue inhibition of T cell proliferation |
|
| DCC2204 | gabra5-agonist-6 | Potent and selective |
|
| DCC2205 | Gac0001e5 Featured | GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies. |
|
| DCC2206 | Gac0003a4 Featured | Novel LXR inverse agonist, functioning as LXR a degrader, significantly reducing LXR protein levels in PDAC cell lines |
|
| DCC2207 | Gadoxetate Disodium | Liver-specific magnetic resonance imaging (MRI) contrast agent |
|
| DCC2208 | Galidesivir Dihydrochloride | Novel viral RNA-dependent RNA polymerase (RdRP) inhibitor |
|
| DCC2209 | Galk-in-36 | Novel inhibitor of galactokinase (GALK) |
|
| DCC2210 | Galunisertib Monohydrate | First-in-class transforming growth factor-β receptor type I inhibitor |
|
| DCC2211 | Gamendazole | Novel male contraceptive agent, blocking spermatogenesis |
|
| DCC2212 | Gamillus | Novel acid-tolerant green RSFP, exhibiting negative switching with especially high contrast in acidic conditions, and its off switching is caused by trans-to-cis isomerization of the chromophore hydroxyphenyl ring that accompanies protonation |
|
| DCC2213 | Gamma-actinorhodin | Natural antibiotic, displaying potent and selective bactericidal activity against key Gram-positive pathogens (including Staphylococcus aureus and enterococci) |
|
| DCC2214 | Gamma-glu-gln | Mammalian metabolite, identified in plasma and cerebrospinal fluid from hyperammonaemic patients |
|
| DCC2215 | Ganstigmine | Novel acetylcholinesterase inhibitor |
|
| DCC2216 | Gas41 Inhibitor 19 | Novel GAS41 YEATS inhibitor, blocking proliferation of NSCLC cells, and modulating expression of GAS41-dependent genes, demonstrating on-target inhibition of GAS41 in cancer cells |
|
| DCC2217 | Gat107 | Novel allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), more active (+)-enantiomer of 4BP-TQS |
|
| DCC2218 | Gat1600 | Novel potent CB1R ago-PAM |
|
| DCC2219 | Gat1601 | Novel CB1R allosteric agonist biased toward G protein- vs β-arrestin1/2-dependent signaling |
|
| DCC2220 | Gat591 | Novel CB1R allosteric agonist-positive modulator (ago-PAM), exhibiting augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55940) |
|
| DCC2221 | Gat592 | Novel CB1R allosteric agonist-positive allosteric modulator (ago-PAM), exhibiting moderate ago-PAM potency and improved aqueous solubility with therapeutic reduction of intraocular pressure in murine glaucoma models |
|
| DCC2222 | Gat593 | Novel CB1R allosteric agonist-positive modulator (ago-PAM), exhibiting augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55940) |
|
| DCC2223 | Gb-115 | Antagonist of central cholecystokinin receptors |
|
| DCC2224 | Gbs-149 | Novel non-toxic and mammalian-specific LINE-1 inhibitor |
|
